Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

latanoprost

&times

Overview

What is LATANOPROST?

Latanoprost is a prostaglandin F analogue. Its chemical name is isopropyl-(Z)-7[(1R,2R,3R,5S)3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate. Its molecular formula is CHO and its chemical structure is:

Latanoprost Ophthalmic Solution 0.005% is supplied as a sterile, isotonic, buffered aqueous solution of latanoprost with a pH of approximately 6.7 and an osmolality of approximately 267 mOsmol/kg. Each mL of Latanoprost Ophthalmic Solution contains 50 micrograms of latanoprost. Benzalkonium chloride, 0.02% is added as a preservative. The inactive ingredients are: sodium chloride, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous, and water for injection. One drop contains approximately 1.5 mcg of latanoprost.



What does LATANOPROST look like?



What are the available doses of LATANOPROST?

Sterile ophthalmic solution containing 50 mcg/mL latanoprost.

What should I talk to my health care provider before I take LATANOPROST?

How should I use LATANOPROST?

Latanoprost Ophthalmic Solution is a prostaglandin F analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.()


What interacts with LATANOPROST?

Sorry No Records found


What are the warnings of LATANOPROST?

Sorry No Records found


What are the precautions of LATANOPROST?

Sorry No Records found


What are the side effects of LATANOPROST?

Sorry No records found


What should I look out for while using LATANOPROST?

Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product.


What might happen if I take too much LATANOPROST?

Intravenous infusion of up to 3 mcg/kg in healthy volunteers produced mean plasma concentrations 200 times higher than during clinical treatment and no adverse reactions were observed. Intravenous dosages of 5.5 to 10 mcg/kg caused abdominal pain, dizziness, fatigue, hot flushes, nausea, and sweating.

If overdosage with Latanoprost Ophthalmic Solution occurs, treatment should be symptomatic.


How should I store and handle LATANOPROST?

StorageStore Pantoprazole Sodium Delayed-Release Tablets, USP at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [ ]. StorageStore Pantoprazole Sodium Delayed-Release Tablets, USP at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [ ]. Latanoprost Sterile Ophthalmic Solution is a clear, isotonic, buffered, preserved colorless solution of latanoprost 0.005% (50 mcg/mL). It is supplied as a 2.5 mL solution filled in a 5 mL translucent low density polyethylene bottle with insert cap assembly comprising of a turquoise coloured, High density Polyethylene screw cap over a Low density Polyethylene nozzle with tamper evident Low density polyethylene dust cover sealing the bottle cap. 2.5 mL fill, 0.005% (50 mcg/mL) Package of 1 bottle NDC: 64980-516-25Storage: Protect from light. Store unopened bottle(s) under refrigeration at 2° to 8°C (36° to 46°F). During shipment to the patient, the bottle may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 8 days. Once a bottle is opened for use, it may be stored at room temperature up to 25°C (77°F) for 6 weeks.Latanoprost Sterile Ophthalmic Solution is a clear, isotonic, buffered, preserved colorless solution of latanoprost 0.005% (50 mcg/mL). It is supplied as a 2.5 mL solution filled in a 5 mL translucent low density polyethylene bottle with insert cap assembly comprising of a turquoise coloured, High density Polyethylene screw cap over a Low density Polyethylene nozzle with tamper evident Low density polyethylene dust cover sealing the bottle cap. 2.5 mL fill, 0.005% (50 mcg/mL) Package of 1 bottle NDC: 64980-516-25Storage: Protect from light. Store unopened bottle(s) under refrigeration at 2° to 8°C (36° to 46°F). During shipment to the patient, the bottle may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 8 days. Once a bottle is opened for use, it may be stored at room temperature up to 25°C (77°F) for 6 weeks.Latanoprost Sterile Ophthalmic Solution is a clear, isotonic, buffered, preserved colorless solution of latanoprost 0.005% (50 mcg/mL). It is supplied as a 2.5 mL solution filled in a 5 mL translucent low density polyethylene bottle with insert cap assembly comprising of a turquoise coloured, High density Polyethylene screw cap over a Low density Polyethylene nozzle with tamper evident Low density polyethylene dust cover sealing the bottle cap. 2.5 mL fill, 0.005% (50 mcg/mL) Package of 1 bottle NDC: 64980-516-25Storage: Protect from light. Store unopened bottle(s) under refrigeration at 2° to 8°C (36° to 46°F). During shipment to the patient, the bottle may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 8 days. Once a bottle is opened for use, it may be stored at room temperature up to 25°C (77°F) for 6 weeks.Latanoprost Sterile Ophthalmic Solution is a clear, isotonic, buffered, preserved colorless solution of latanoprost 0.005% (50 mcg/mL). It is supplied as a 2.5 mL solution filled in a 5 mL translucent low density polyethylene bottle with insert cap assembly comprising of a turquoise coloured, High density Polyethylene screw cap over a Low density Polyethylene nozzle with tamper evident Low density polyethylene dust cover sealing the bottle cap. 2.5 mL fill, 0.005% (50 mcg/mL) Package of 1 bottle NDC: 64980-516-25Storage: Protect from light. Store unopened bottle(s) under refrigeration at 2° to 8°C (36° to 46°F). During shipment to the patient, the bottle may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 8 days. Once a bottle is opened for use, it may be stored at room temperature up to 25°C (77°F) for 6 weeks.Latanoprost Sterile Ophthalmic Solution is a clear, isotonic, buffered, preserved colorless solution of latanoprost 0.005% (50 mcg/mL). It is supplied as a 2.5 mL solution filled in a 5 mL translucent low density polyethylene bottle with insert cap assembly comprising of a turquoise coloured, High density Polyethylene screw cap over a Low density Polyethylene nozzle with tamper evident Low density polyethylene dust cover sealing the bottle cap. 2.5 mL fill, 0.005% (50 mcg/mL) Package of 1 bottle NDC: 64980-516-25Storage: Protect from light. Store unopened bottle(s) under refrigeration at 2° to 8°C (36° to 46°F). During shipment to the patient, the bottle may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 8 days. Once a bottle is opened for use, it may be stored at room temperature up to 25°C (77°F) for 6 weeks.Latanoprost Sterile Ophthalmic Solution is a clear, isotonic, buffered, preserved colorless solution of latanoprost 0.005% (50 mcg/mL). It is supplied as a 2.5 mL solution filled in a 5 mL translucent low density polyethylene bottle with insert cap assembly comprising of a turquoise coloured, High density Polyethylene screw cap over a Low density Polyethylene nozzle with tamper evident Low density polyethylene dust cover sealing the bottle cap. 2.5 mL fill, 0.005% (50 mcg/mL) Package of 1 bottle NDC: 64980-516-25Storage: Protect from light. Store unopened bottle(s) under refrigeration at 2° to 8°C (36° to 46°F). During shipment to the patient, the bottle may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 8 days. Once a bottle is opened for use, it may be stored at room temperature up to 25°C (77°F) for 6 weeks.


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

Non-Clinical Toxicology
Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product.

Life-Threatening Respiratory Depression

Discuss the risk of respiratory depression with patients, explaining that the risk is greatest when starting methadone hydrochloride oral concentrate or when the dose is increased . Advise patients how to recognize respiratory depression and to seek medical attention if they are experiencing breathing difficulties.

Symptoms of Arrhythmia

Instruct patients to seek medical attention immediately if they experience symptoms suggestive of an arrhythmia (such as palpitations, near syncope, or syncope) when taking methadone hydrochloride oral concentrate.

Accidental Ingestion

Inform patients that accidental ingestion, especially by children, may result in respiratory depression or death . Instruct patients to take steps to store methadone hydrochloride oral concentrate securely. Advise patients to dispose of unused methadone hydrochloride oral concentrate by flushing down the toilet.

Abuse Potential

Inform patients that methadone hydrochloride oral concentrate contains methadone, a Schedule II controlled substance that is subject to abuse . Instruct patients not to share methadone hydrochloride oral concentrate with others and to take steps to protect methadone hydrochloride oral concentrate from theft or misuse.

Risks from Concomitant Use of Alcohol and other CNS Depressants

Inform patients that the concomitant use of alcohol with methadone can increase the risk of life-threatening respiratory depression. Instruct patients not to consume alcoholic beverages, as well as prescription and over-the-counter drug products that contain alcohol, during treatment with methadone hydrochloride oral concentrate .

Inform patients that potentially serious additive effects may occur if methadone is used with other CNS depressants, and not to use such drugs unless supervised by a health care provider.





Instruct patients how to properly take methadone hydrochloride oral concentrate, including the following:

Serotonin Syndrome:

Inform patients that methadone hydrochloride oral concentrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away if symptoms develop. Instruct patients to inform their physicians if they are taking, or plan to take serotonergic medications (see and ).

MAOI Interaction

Inform patients to avoid taking methadone hydrochloride oral concentrate while using any drugs that inhibit monoamine oxidase. Patients should not start MAOIs while taking methadone hydrochloride oral concentrate .

Adrenal Insufficiency:

Inform patients that methadone hydrochloride oral concentrate could cause adrenal insufficiency, a potentially life-threatening condition. Adrenal insufficiency may present with non-specific symptoms and signs such as nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. Advise patients to seek medical attention if they experience a constellation of these symptoms.

Anaphylaxis

Inform patients that anaphylaxis has been reported with ingredients contained in methadone hydrochloride oral concentrate. Advise patients how to recognize such a reaction and when to seek medical attention .

Neonatal Opioid Withdrawal

Advise women that if they are pregnant while being treated with methadone hydrochloride oral concentrate, the baby may have signs of withdrawal at birth and that withdrawal is treatable.

Lactation

Instruct nursing mothers using methadone hydrochloride oral concentrate to watch for signs of methadone toxicity in their infants, which include increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness. Instruct nursing mothers to talk to their baby’s healthcare provider immediately if they notice these signs. If they cannot reach the healthcare provider right away, instruct them to take the baby to the emergency room or call 911 (or local emergency services) .

Constipation

Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention .

Latanoprost Ophthalmic Solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as latanoprost is administered.

The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of latanoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. Beyond 5 years the effects of increased pigmentation are not known [ ].

Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with Latanoprost Ophthalmic Solution can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly [ ].

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).